Infinity Pharmaceuticals acts on the endless possibilities for new cancer treatments. The firm works to discover and develop targeted therapies for different types of cancer, inflammatory conditions, and pain. Such targeted therapies aim at inhibiting specific disease signaling pathways and proteins. Infinity Pharmaceuticals has several candidates in clinical trials, including some that are being investigated in combination with existing cancer treatments. Candidates include IPI-926 (also known as Hedgehog) to treat several types of cancer, as well as IPI-504, also for cancer, IPI-940 to treat inflammation and pain, and IPI-145 for cancer and inflammatory diseases.